Home > Healthcare > Medical Devices > Therapeutic Devices > U.S. Intrauterine Devices Market
U.S. Intrauterine Devices Market - By Product (Copper IUD, Hormonal IUD), By Age Group (15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45+), Competitive Market Share & Forecast, 2023-2032
- Report ID: GMI2895
- Published Date: Mar 2023
- Report Format: PDF
U.S. Intrauterine Devices Market Size
U.S. Intrauterine Devices Market size was valued at over USD 1.3 billion in 2022. Driven by the supportive regulatory scenario, the market is poised to grow at over 9.5% CAGR from 2023 to 2032.
The U.S. government is the largest donor to family planning and reproductive health in the world. Additionally, it is one of the largest distributor and consumer of contraceptives globally.
Unintended pregnancies cost the U.S. healthcare system around USD 11 billion every year. With growing innovations in the field, the U.S. FDA is granting approval to novel IUDs for the prevention of unintended pregnancies and abortions.
The use of intrauterine contraceptive devices for younger women and those who have never given birth has also been approved by the U.S. FDA. Such a favorable regulatory environment will create a strong impetus for industry progress.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| U.S. Intrauterine Devices Market Size in 2022: | USD 1.3 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 9.7% |
| 2032 Value Projection: | USD 3.4 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 210 |
| Tables, Charts & Figures: | 298 |
| Segments covered: | Type, Products and Services, End-use, and Zone. |
| Growth Drivers: | |
| Pitfalls & Challenges: |
Steep prices of intrauterine devices may impede industry development
Despite a broad scope for product adoption, the high price of IUDs as a substitute for other contraceptive products may hamper U.S. intrauterine devices market demand. They have a higher upfront cost than oral solutions such as ulipristal acetate and levonorgestrel. In fact, the hormonal IUD of Bayer AG, the German multinational pharmaceutical and biotechnology company, Mirena, costs around USD 1,049, which is not seem cost-effective for many women who wish to plan their pregnancy. However, many IUDs come with insurance coverage, which may favor their adoption.
U.S. Intrauterine Devices Market Analysis
On the basis of product, the U.S. intrauterine devices market from the hormonal IUD segment is expected to show a growth rate of more than 10% through 2032. Hormonal IUDs are suitable for people who cannot use estrogen and also help with painful menstrual cycles. They have shown 99% efficacy in pregnancy prevention, making them that much more preferred among women. In addition, they offer non-contraceptive benefits, are safe, and people suffering from endometriosis, fibroids, anemia, and menstrual flow can use them.
Based on age group, the U.S. intrauterine devices market from the 30-34 segment is anticipated to record a valuation of over USD 867.5 million by 2032, on account of growing abortion rates and unwanted pregnancies among women of this age group. The segment expansion can also be credited to surging awareness about different IUDs and their uses among females in the U.S.
Based on zone, the South Atlantic segment accounted for over 20% of the U.S. intrauterine devices market revenue share in 2022, driven by growing government and non-government initiatives towards family planning. Efforts towards expanding access to IUDs for preventing unintended pregnancies and abortions are creating a high impetus for market development. In fact, in states such as Florida, family planning and the associated preventive health services are available to both male and female populations in all 67 counties through the contracted agencies and local county health units.
U.S. Intrauterine Devices Market Share
Some leading U.S. intrauterine devices market players include
- Bayer AG
- Allergan (AbbVie, Inc.)
- CooperSurgical Inc
Many of these firms are focusing on product innovations and FDA approvals to sustain their industry leadership. Citing an instance, in August 2021, Bayer AG, a German multinational pharma and biotech firm, received U.S. FDA approval for a supplemental new drug application which extends the use of its IUD Mirena® 52 mg to make it usable for up to 8 years.
Furthermore, results from a phase 3 extension trial which analyzes the safety and efficacy of Mirena serve as the foundation of this approval. This strategic move benefitted the company by enhancing its product portfolio of IUDs, which boosted its revenue.
Impact of COVID-19 Pandemic
The COVID-19 pandemic impacted the U.S. intrauterine devices industry negatively as the modified SOPs and social distancing norms hampered the operations of gynecology centers. These centers emphasized only the emergency requirements and either suspended or delayed their daily operations. As per the International Journal of Gynecology & Obstetrics, the obstructions in supply chain led to a shortage of contraceptive techniques featuring IUDs across various zones in the country.
In fact, the Family Planning National Training Center (FPNTC) compiled a list of suggestions to help clinics and gynecologic hospitals cater to customers’ requirements while emphasizing their and customers’ safety. However, the resumption of regular operations of clinics and gynecology hospitals with the decreasing number of COVID-19 infections in many zones in the U.S. restored the demand for the product to the pre-pandemic level.
The U.S. intrauterine devices market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million and volume in Units from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Product
- Copper IUD
- Hormonal IUD
By Age Group
- 15-19
- 20-24
- 25-29
- 30-34
- 35-39
- 40-44
- 45+
The above information is provided for the following zones:
- East North Central
- Illinois
- Indiana
- Michigan
- Ohio
- Wisconsin
- West South Central
- Arkansas
- Louisiana
- Oklahoma
- Texas
- South Atlantic
- Delaware
- Florida
- Georgia
- Maryland
- North Carolina
- South Carolina
- Virginia
- West Virginia
- Washington, D.C.
- North East
- Connecticut
- Maine
- Massachusetts
- New Hampshire
- Rhode Island
- Vermont
- New Jersey
- New York
- Pennsylvania
- East South Central
- Alabama
- Kentucky
- Mississippi
- Tennessee
- West North Central
- Iowa
- Kansas
- Minnesota
- Missouri
- Nebraska
- North Dakota
- South Dakota
- Pacific Central
- Alaska
- California
- Hawaii
- Oregon
- Washington
- Mountain States
- Arizona
- Colorado
- Utah
- Nevada
- New Mexico
- Idaho
- Montana
- Wyoming
Frequently Asked Questions (FAQ) :
U.S. Intrauterine Devices Market Scope
